文献速递系统性红斑狼疮

晚发性与早发性系统性红斑狼疮:RELESSER全国多中心登记研究特征与结局对比

Late-onset versus early-onset systemic lupus: characteristics and outcome in a national multicentre register (RELESSER).
PubMed 文献 · Rheumatology (Oxford) · 2021-01-01

基于西班牙风湿病学会RELESSER登记数据库3619例SLE患者的横断面回顾性研究,将诊断年龄≥50岁定义为晚发性(565例,15.6%),<50岁为早发性(3054例,84.4%)。晚发性SLE合并症更多、诊断延迟更长,更常出现浆膜炎、重性抑郁、血栓事件、心脏受累及狼疮抗凝物阳性,免疫抑制剂使用更少,死亡率更高(14.3% vs 4.7%,P<0.001)。

要点

  • 晚发性SLE占15.6%,男女比为5:1,98.7%为白种人。
  • 晚发性SLE诊断延迟更长、合并症更多,以心血管疾病最常见。
  • 晚发性SLE死亡率14.3%,显著高于早发性4.7%。

核心结论

  • 晚发性SLE起病隐匿、临床表现不典型,易致诊断错误,病情活动度总体较低、免疫抑制剂使用较少,但死亡率更高。

研究设计与样本

  • 西班牙风湿病学会RELESSER全国SLE患者登记数据库的横断面回顾性研究,共纳入3619例患者。
  • 晚发性SLE定义为诊断年龄≥50岁(565例,15.6%),早发性为<50岁(3054例,84.4%)。

主要发现

  • 晚发性组诊断时平均(s.d.)年龄为57.4(10.4)岁,男女比为5:1,98.7%为白种人。
  • 晚发性组诊断时合并症多于早发性组,其中心血管疾病最常见(P<0.005)。
  • 诊断延迟在晚发性组更长[45.3(3.1)vs 28.1(1.0);P<0.001]。
  • 校正诊断后病程后,晚发性组更常出现浆膜炎、重性抑郁、血栓事件、心脏受累及狼疮抗凝物阳性。
  • 晚发性组免疫抑制剂处方更少,死亡率更高(14.3% vs 4.7%;P<0.001)。

关键数值与推荐

  • 晚发性SLE定义:诊断年龄≥50岁;早发性SLE定义:诊断年龄<50岁。
  • 晚发性组死亡率14.3%,早发性组4.7%(P<0.001)。
  • 诊断延迟:晚发性组45.3(3.1),早发性组28.1(1.0)(P<0.001)。

临床怎么用

  • 对≥50岁起病、表现不典型(如浆膜炎、心脏受累、血栓事件)的患者应警惕晚发性SLE,减少诊断延误。
  • 晚发性SLE治疗中免疫抑制剂使用较少,需权衡疾病活动度与年龄相关合并症。
  • 晚发性SLE死亡风险更高,长期随访中应关注死因与病程或年龄相关合并症的关系。

局限性

  • 本研究为横断面回顾性设计,无法确定因果关系。
  • 原文指出需长期前瞻性研究以明确该人群死因是否与临床病程或年龄相关合并症有关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The aim of the present study was to describe the demographic, clinical and immunological characteristics of patients with late-onset (≥50 years) SLE vs patients with early-onset SLE (<50 years). METHODS: We performed a cross-sectional retrospective study of 3619 patients from the RELESSER database (National Register of Patients with Systemic Lupus Erythematosus of the Spanish Society of Rheumatology). RESULTS: A total of 565 patients (15.6%) were classified as late-onset SLE and 3054 (84.4%) as early-onset SLE. The male-to-female ratio was 5:1. Mean (s.d.) age at diagnosis in the late-onset group was 57.4 (10.4) years. At diagnosis, patients with late-onset SLE had more comorbid conditions than patients with early-onset SLE; the most frequent was cardiovascular disease (P <0.005). Furthermore, diagnostic delay was longer in patients with late-onset SLE [45.3 (3.1) vs 28.1 (1.0); P <0.001]. Almost all patients with late-onset SLE (98.7%) were Caucasian. Compared with early-onset SLE and after adjustment for time since diagnosis, patients with late-onset SLE more frequently had serositis, major depression, thrombotic events, cardiac involvement and positive lupus anticoagulant values. They were also less frequently prescribed immunosuppressive agents. Mortality was greater in late-onset SLE (14.3% vs 4.7%; P <0.001). CONCLUSION: Late-onset SLE is insidious, with unusual clinical manifestations that can lead to diagnostic errors. Clinical course is generally indolent. Compared with early-onset disease, activity is generally reduced and immunosuppressants are less commonly used. Long-term prospective studies are necessary to determine whether the causes of death are associated with clinical course or with age-associated comorbidities in this population.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Riveros Frutos A, Holgado S, Sanvisens Bergé A, et al. Late-onset versus early-onset systemic lupus: characteristics and outcome in a national multicentre register (RELESSER). Rheumatology (Oxford). 2021. PMID: 33106841. doi:10.1093/rheumatology/keaa477

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。